دورية أكاديمية
Saponins from Allii Macrostemonis Bulbus attenuate atherosclerosis by inhibiting macrophage foam cell formation and inflammation.
العنوان: | Saponins from Allii Macrostemonis Bulbus attenuate atherosclerosis by inhibiting macrophage foam cell formation and inflammation. |
---|---|
المؤلفون: | Zhao S; Translational Medicine Centre, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China., Guo H; Translational Medicine Centre, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China., Qiu L; Translational Medicine Centre, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China., Zhong C; Translational Medicine Centre, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.; Department of Cardiovascular Sciences and Center for Metabolic Disease Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA., Xue J; Translational Medicine Centre, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China., Qin M; Translational Medicine Centre, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China., Zhang Y; Translational Medicine Centre, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China., Xu C; Translational Medicine Centre, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China. xuchuanming2008@163.com., Xie Y; Translational Medicine Centre, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China. 1047501830@qq.com., Yu J; Department of Cardiovascular Sciences and Center for Metabolic Disease Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA. |
المصدر: | Scientific reports [Sci Rep] 2024 Jun 05; Vol. 14 (1), pp. 12917. Date of Electronic Publication: 2024 Jun 05. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: London : Nature Publishing Group, copyright 2011- |
مواضيع طبية MeSH: | Foam Cells*/drug effects , Foam Cells*/metabolism , Atherosclerosis*/drug therapy , Atherosclerosis*/pathology , Atherosclerosis*/metabolism , Atherosclerosis*/prevention & control , Saponins*/pharmacology , Inflammation*/drug therapy , Inflammation*/pathology, Animals ; Mice ; Allium/chemistry ; Male ; Apolipoproteins E/deficiency ; Diet, High-Fat/adverse effects ; NF-kappa B/metabolism ; Mice, Inbred C57BL ; Lipoproteins, LDL/metabolism |
مستخلص: | Allii Macrostemonis Bulbus (AMB) is a traditional Chinese medicine with medicinal and food homology. AMB has various biological activities, including anti-coagulation, lipid-lowering, anti-tumor, and antioxidant effects. Saponins from Allium macrostemonis Bulbus (SAMB), the predominant beneficial compounds, also exhibited lipid-lowering and anti-inflammatory properties. However, the effect of SAMB on atherosclerosis and the underlying mechanisms are still unclear. This study aimed to elucidate the pharmacological impact of SAMB on atherosclerosis. In apolipoprotein E deficiency (ApoE -/- ) mice with high-fat diet feeding, oral SAMB administration significantly attenuated inflammation and atherosclerosis plaque formation. The in vitro experiments demonstrated that SAMB effectively suppressed oxidized-LDL-induced foam cell formation by down-regulating CD36 expression, thereby inhibiting lipid endocytosis in bone marrow-derived macrophages. Additionally, SAMB effectively blocked LPS-induced inflammatory response in bone marrow-derived macrophages potentially through modulating the NF-κB/NLRP3 pathway. In conclusion, SAMB exhibits a potential anti-atherosclerotic effect by inhibiting macrophage foam cell formation and inflammation. These findings provide novel insights into potential preventive and therapeutic strategies for the clinical management of atherosclerosis. (© 2024. The Author(s).) |
References: | Curr Top Med Chem. 2005;5(3):265-82. (PMID: 15857310) Nat Rev Cardiol. 2021 Oct;18(10):712-723. (PMID: 33833449) Endocrinol Metab Clin North Am. 2022 Sep;51(3):655-679. (PMID: 35963634) Nat Rev Drug Discov. 2021 Aug;20(8):589-610. (PMID: 33976384) Chem Res Toxicol. 2021 Sep 20;34(9):2125-2134. (PMID: 34428026) Circ Res. 2011 Apr 15;108(8):985-95. (PMID: 21350215) Nature. 2019 May;569(7757):565-569. (PMID: 31019307) Nat Rev Cardiol. 2022 Apr;19(4):228-249. (PMID: 34759324) Molecules. 2023 Mar 08;28(6):. (PMID: 36985457) Cardiovasc Res. 2023 Oct 24;119(13):2278-2293. (PMID: 37595265) Open Heart. 2018 Jan 26;5(1):e000722. (PMID: 29387429) Vascul Pharmacol. 2019 Jan;112:54-71. (PMID: 30115528) Nat Commun. 2016 Nov 28;7:13457. (PMID: 27892461) Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17511-6. (PMID: 19805174) Phytomedicine. 2023 Oct;119:155002. (PMID: 37572566) Circ Res. 2012 Mar 16;110(6):889-900. (PMID: 22427326) Circ Res. 2023 May 26;132(11):1521-1545. (PMID: 37228232) Eur J Pharmacol. 2008 Dec 3;599(1-3):159-65. (PMID: 18930725) Nat Commun. 2023 Feb 18;14(1):929. (PMID: 36807553) Curr Opin Lipidol. 2020 Oct;31(5):273-278. (PMID: 32773464) Circulation. 2007 Oct 16;116(16):1832-44. (PMID: 17938300) Br Med Bull. 2018 Jun 1;126(1):101-112. (PMID: 29534172) Nat Rev Immunol. 2015 Feb;15(2):104-16. (PMID: 25614320) Curr Drug Targets. 2011 May;12(5):647-60. (PMID: 21039336) J Cell Mol Med. 2016 Jan;20(1):17-28. (PMID: 26493158) Circ Res. 2016 Feb 19;118(4):653-67. (PMID: 26892964) Nature. 2021 Apr;592(7855):524-533. (PMID: 33883728) J Intern Med. 2015 Nov;278(5):483-93. (PMID: 26260307) Nat Rev Immunol. 2010 Mar;10(3):210-5. (PMID: 20168318) Chin J Nat Med. 2016 Jul;14(7):481-98. (PMID: 27507199) Nat Rev Cardiol. 2019 Dec;16(12):727-744. (PMID: 31243391) Cell Death Dis. 2023 Oct 20;14(10):691. (PMID: 37863894) Exp Mol Med. 2014 Jun 06;46:e99. (PMID: 24903227) Nat Commun. 2017 Jun 07;8:15750. (PMID: 28589926) Nat Immunol. 2013 Aug;14(8):812-20. (PMID: 23812099) Cells. 2022 Mar 17;11(6):. (PMID: 35326465) Arterioscler Thromb Vasc Biol. 2003 Sep 1;23(9):1553-8. (PMID: 12869351) Pharmacol Rev. 2019 Oct;71(4):596-670. (PMID: 31554644) Circ Res. 2019 Dec 6;125(12):1087-1102. (PMID: 31625810) Circulation. 2021 Feb 23;143(8):e254-e743. (PMID: 33501848) Molecules. 2024 Mar 11;29(6):. (PMID: 38542876) |
معلومات مُعتمدة: | 82160051 National Natural Science Foundation of China; 32100908 National Natural Science Foundation of China |
فهرسة مساهمة: | Keywords: Atherosclerosis; Inflammation; Macrophage; Saponins from Allii Macrostemonis Bulbus |
المشرفين على المادة: | 0 (Saponins) 0 (Apolipoproteins E) 0 (NF-kappa B) 0 (Lipoproteins, LDL) |
تواريخ الأحداث: | Date Created: 20240605 Date Completed: 20240605 Latest Revision: 20240608 |
رمز التحديث: | 20240608 |
مُعرف محوري في PubMed: | PMC11153636 |
DOI: | 10.1038/s41598-024-61209-w |
PMID: | 38839811 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2045-2322 |
---|---|
DOI: | 10.1038/s41598-024-61209-w |